Adi Kartolo

Adi Kartolo

Auto-generated profile, based on publicly available information

Adi Kartolo

Kingston Health Sciences Centre, Kingston, Ontario, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Immunotherapy
Verified
Journal Article
Closed access
CYCynthia Cynthia Yeung
Cynthia Cynthia Yeung
AKAdi Kartolo
Adi Kartolo
JTJustin Tong
Justin Tong
WHWilma Hopman
Wilma Hopman
TBTara Baetz
Tara Baetz
Aims: Chronomodulation of immune checkpoint inhibitors (ICIs) is not well understood. The authors evaluated the circadian timing of initial ICI infusions. Patients & methods: A retrospective cohort... Tweetable abstract Later time of day of the first several infusions of immune checkpoint inhibitors was associated with worse overall survival in patients with advanced melanoma.

11 November 2021 in Immunotherapy
Verified
Journal Article
Closed access
AKAdi Kartolo
Adi Kartolo
CYCynthia Cynthia Yeung
Cynthia Cynthia Yeung
GMGordon T Moffat
Gordon T Moffat
LHLilian Hanna
Lilian Hanna
WHWilma Hopman
Wilma Hopman
TBTara Baetz
Tara Baetz
Aim: To evaluate the correlation between venous thromboembolism events (VTEs) and immune checkpoint inhibitor (ICI)-based regimens. Methods: This is a retrospective study of 403 patients with advan...

1 November 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AKAdi Kartolo
Adi Kartolo
ITIan F. Tannock
Ian F. Tannock
FBFrancisco E. Vera Badillo
Francisco E. Vera Badillo
Triplet therapy may be a viable but should not be the default option for all men with mHSPC

28 January 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
AKA Kartolo
A Kartolo
RHR Holstead
R Holstead
WHW Hopman
W Hopman
LYL Young
L Young
TBT Baetz
T Baetz
Aim: To evaluate the impact of discrepancy between prescribed and recommended fixed 200 mg dose (P-F discrepancy) on immune-related adverse events (irAEs) and treatment efficacy in patients with advanced melanoma and NSCLC. Methods: This retrospective study included 177 patients with advanced melanoma or non-small cell lung cancer (NSCLC) who received at least one cycle of single-agent pembrolizumab. We defined P-F discrepancy as the differences between prescribed pembrolizumab dose and 200 mg recommended dose, expressed in percentages. Our primary outcome was immune-related adverse events (irAEs), and our secondary outcomes included overall survival (OS) and progression free survival (PFS). Results: The median P-F discrepancy was –21.5%, with the 25th and 75th percentile at –32% and –5.0% respectively. ROC curve analyses did not show any optimal cutoffs to prognosticate irAEs (AUC = 0.558 for all patients) or cancer mortality (AUC = 0.583 for melanoma; AUC = 0.539 for NSCLC) in either cancer type. Separate multivariable Cox analyses suggested no statistically significant association between P-F discrepancy and overall survival in patients with melanoma (HR 1.012, 95%CI 0.987–1.038, P = 0.362) or NSCLC (HR 0.998, 95%CI 0.978–1.019, P = 0.876). Conclusion: There was no optimal pembrolizumab cut-off point to predict irAEs or treatment efficacy. We supported the use of weight-based pembrolizumab dosing, given the potential cost-saving and no differences in terms of irAEs or treatment efficacy in patients with advanced melanoma or NSCLC. Future studies on province- or national-level would be important to validate our findings.

3 March 2017 in International Journal of Cancer Studies & Research
Verified
Journal Article
Open access
KAKartolo A
Kartolo A
WCWong C
Wong C
CSCheng S
Cheng S